Lais Ragweed I (Ambrosia Artemisiifolia (302))

Ambrosia artemisiifolia, the ragweed extract in Lais Ragweed I, stimulates the immune system to shift from a Th2‑dominant allergic response toward a regulatory Th1/Treg profile. This change lowers specific IgE levels and raises IgG4 blocking antibodies, creating clinical tolerance to ragweed pollen.

The dosing regimen for Lais Ragweed I is individualized. A qualified healthcare professional determines the starting dose, escalation schedule and maintenance dose based on the patient’s sensitivity, age, and clinical response. No fixed dose can be provided without a prescriber’s assessment.

Safety data for Lais Ragweed I in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful evaluation.

To order Lais Ragweed I, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Lais Ragweed I is an oromucosal ragweed extract, similar in principle to sublingual tablets and injectable extracts from other manufacturers. Compared with injectable forms, the oromucosal route is non‑invasive and can be self‑administered under supervision, while offering comparable efficacy in inducing tolerance when used according to approved protocols.

Store Lais Ragweed I at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposure to extreme temperatures. Follow any additional handling instructions provided by the supplier to maintain product stability.

Lais Ragweed I is administered via the oromucosal route, typically as a sublingual or buccal preparation placed under the tongue or against the cheek. The exact administration technique and dosing schedule are defined by the prescribing clinician and should be followed precisely to ensure safety and effectiveness.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema, bronchospasm and severe urticaria. Patients should be monitored during dose escalation, and any signs of a severe reaction require immediate medical attention, including emergency treatment with epinephrine if indicated.

Lais Ragweed I should not be used by individuals with a known severe hypersensitivity to ragweed pollen extract or any component of the formulation. Patients with uncontrolled asthma, active severe allergic disease, or those receiving conflicting immunotherapies without medical supervision should also avoid its use.